"We are going to bring scientific expertise and our global network into the partnership and gradually continue our financial commitment. Our joint venture with Victhom's Neurobionix division will strengthen our research and development activities in neurostimulation over the long term. As a growing global medical technology company, Otto Bock HealthCare has the strength to ensure that the developments and products in our product range will reach successfully the global healthcare markets and increase the quality of life of the patients in their daily life", says Hans Georg Näder, President and CEO of Otto Bock HealthCare, explaining the activity.
Further information about the proposed transaction and the terms and conditions of the concurrent plan of arrangement will be available on SEDAR (www.sedar.com).
Update on Filing of Annual Disclosure Documents
In accordance with NP 12-203 and as previously announced, Victhom had voluntarily requested that the Autorite des marches financiers and other Canadian securities regulatory authorities issue a temporary order that prohibits certain directors, officers and insiders of Victhom from trading in securities of Victhom for as long as the annual financial statements, CEO and CFO certifications, and related MD&A and AIF are not filed (the "Management Cease Trade Order").
Following the above announcement, which constitutes a material change respecting Victhom and its activities, Victhom anticipates that the release of its annual financial statements, CEO and CFO certifications and related MD&A and AIF will occur in the next few days and that Victhom will apply to relevant authorities afterwards to request the revocation of the Management Cease Trade Order.
Victhom discovers, develops and manufacture
|SOURCE VICTHOM HUMAN BIONICS INC.|
Copyright©2009 PR Newswire.
All rights reserved